The CRISPR Licensing Landscape

@LSPN May 3-4th, 2023, Boston MA

Contact Michael.Arciero@ersgenomics.com for more information.

favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology.
 Our founder, Dr. Emmanuelle Charpentier  won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

CRISPR/Cas9 has transformed the field of gene editing. At ERS, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 

Michael Arciero, VP IP & Commercial Development with ERS Genomics will speak at this year’s Life Sciences Patent Network (LSPN) in Boston, May 3-4. 

Attend this session to understand:

1. The current CRISPR Licensing Landscape

2. Common misperceptions: Fact vs. Fction

3. The patent batttle – what’s next?

4. Do you need a license?

5. Regional differences – what geolocation means for your licensing requirements.


CRISPR/Cas9 is a patented invention, so any commerical use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape is clearer than you might think.

Contact Michael.Arciero@ersgenomics.com to secure your CRISPR/Cas9 license.

 

Schedule time with:

Michael Arciero, Vice President IP & Commercial Development

‘This is a lot of misinformation in circulation when it comes to the CRISPR licensing landscape. In speaking at LSPN, my goal is to cut through the noise and provide straightforward answers to common misperceptions.’

Schedule a Meeting

Licensing

Learn More

Intellectual Property

Learn More

Knowledge Centre

Learn More

Contact US

Learn More

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 technology. Dublin, Ireland and Vancouver, Canada, 1st June 2023:  ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Applied Biological Materials Inc (‘abm,’). This is a.

Read Full Article

LSPN Boston 2023: Life Science IP Review

“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is clearer in the EPO opposition division which has affirmed the CVC foundational CRISPR patents over numerous opponents,” highlights Michael Arciero, VP, IP & Corporate Development

Read Full Article

BIO Europe, Basel 2023: Our thoughts

#BIO Europe is one of the most important Life Science events for people in the industry to attend. This year was no exception. ERS Senior Director, Dr. Ralph Vogelsang offers his thoughts on the recent Basle event in this quick read: https://lnkd.in/eET6s-rN

Read Full Article